Literature DB >> 29621215

Rollout of high-priced cell and gene therapies forces payer rethink.

Melanie Senior.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29621215     DOI： 10.1038/nbt0418-291a

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  1 in total

1.  FDA approves hereditary blindness gene therapy.

Authors: 
Journal:  Nat Biotechnol       Date:  2018-01-10       Impact factor: 54.908
  1 in total
  3 in total

1.  Sangamo poised for CAR-Treg race.

Authors: 
Journal:  Nat Biotechnol       Date:  2018-09-06       Impact factor: 54.908

Review 2.  Addressing the Value of Gene Therapy and Enhancing Patient Access to Transformative Treatments.

Authors:  Rachel Salzman; Francesca Cook; Timothy Hunt; Harry L Malech; Philip Reilly; Betsy Foss-Campbell; David Barrett
Journal:  Mol Ther       Date:  2018-10-30       Impact factor: 11.454

3.  Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options.

Authors:  Rositsa Koleva-Kolarova; James Buchanan; Heleen Vellekoop; Simone Huygens; Matthijs Versteegh; Maureen Rutten-van Mölken; László Szilberhorn; Tamás Zelei; Balázs Nagy; Sarah Wordsworth; Apostolos Tsiachristas
Journal:  Appl Health Econ Health Policy       Date:  2022-04-04       Impact factor: 3.686
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.